Last updated: March 15, 2026
What is NDC 54436-0200?
NDC 54436-0200 refers to Brolucizumab injection (brand name Beovu), used for the treatment of neovascular age-related macular degeneration (nAMD). Approved by the FDA in October 2019, it is a vascular endothelial growth factor (VEGF) inhibitor designed to reduce treatment burden via less frequent dosing.
Market Size and Demand Dynamics
Current Market Environment
- The global age-related macular degeneration (AMD) market was valued at approximately USD 3.5 billion in 2022.
- The nAMD segment accounts for roughly 65% of the AMD market, equating to USD 2.28 billion in 2022.
- Beovu held an estimated 15% market share among anti-VEGF injectables for nAMD in 2022, trailing off competition from Lucentis and Eylea due to market penetration challenges.
Demographic and Epidemiological Factors
- AMD affects approximately 200 million individuals globally, with 10–15% having nAMD.
- The age group 65+ is the primary patient population; the U.S. Census projects 20% of the population over 65 by 2030.
- The incidence of nAMD increases with age, with approximately 15% of patients requiring ongoing anti-VEGF therapy per year.
Competitive Landscape
| Product |
Market Share (2022) |
Dosing Interval |
Price (per injection) |
Clinical Differentiation |
| Eylea (aflibercept) |
40% |
Every 8 weeks |
USD 2,000 |
Broad approval, established presence |
| Lucentis (ranibizumab) |
35% |
Monthly to every 8 weeks |
USD 2,100 |
Extensive clinical history |
| Beovu (brolucizumab) |
15% |
Every 12 weeks |
USD 1,850 |
Higher concentration, less frequent dosing |
Market Drivers and Barriers
- Drivers: Longer dosing intervals improve patient adherence; high unmet need for reducing injection burden; potential for expanding use in other ocular diseases.
- Barriers: Safety concerns over intraocular inflammation and vasculitis; limited long-term real-world data; competition from established therapies with strong clinical data.
Price Projections
Current Pricing
- Average wholesale price (AWP) per injection: USD 1,850–2,100.
- Actual reimbursement rates vary; hospitals and clinics often negotiate lower prices.
Future Price Trajectory
- Expected stabilization price around USD 1,800–2,000 per injection through 2025.
- Replacement of more frequent therapies (monthly) could justify a slight premium due to convenience.
- Price declines likely to be limited absent significant patent challenges or biosimilar entry.
Revenue Projections (2023–2027)
| Year |
Estimated Market Penetration |
Projected Revenue (USD billions) |
Notes |
| 2023 |
20% |
0.54 |
Initial uptake; safety concerns limit expansion |
| 2024 |
25% |
0.68 |
Expanded use in eligible patients |
| 2025 |
30% |
0.85 |
Clinical data supports broader adoption |
| 2026 |
35% |
1.0 |
Increased approval in additional indications |
| 2027 |
40% |
1.2 |
Sustained growth, market saturation |
Assumption: Average price per injection remains stable.
Risks Impacting Market and Price
- Safety profile issues such as vasculitis may reduce acceptance.
- Entry of biosimilars could pressure prices.
- Demonstration of comparable efficacy to existing drugs might limit pricing power.
- Regulatory constraints on off-label uses or additional indications.
Key Takeaways
- NDC 54436‑0200 (Beovu) is positioned as a longer-acting anti-VEGF for nAMD, with a base price hovering around USD 1,850–2,100 per injection.
- The market is competitive, with Eylea and Lucentis dominating share; Beovu's adoption is influenced by safety profile and dosing benefits.
- Revenue growth depends heavily on clinical acceptance, safety profile, and market penetration, projected to reach USD 1.2 billion by 2027.
- Price stability is expected in the near term, with potential downward pressure from biosimilars and competitive responses.
FAQs
Q1: How does Beovu’s dosing schedule compare to its competitors?
A: Beovu is administered every 12 weeks after the loading phase, compared to Eylea and Lucentis, which typically require monthly or bi-monthly injections.
Q2: What factors could lead to price reductions for Beovu?
A: Biosimilar competition, safety profile concerns, and mature market dynamics could pressure prices downward.
Q3: Are there ongoing clinical trials that might expand Beovu’s indications?
A: Yes, studies are evaluating bevacizumab biosimilars and potential use in other retinal diseases, which could influence market dynamics.
Q4: What impact would biosimilar entrants have on market share?
A: Biosimilars could capture significant share, potentially reducing prices by 20–40%, depending on market uptake.
Q5: How significant are safety concerns in Beovu’s market performance?
A: Safety issues, particularly intraocular inflammation and vasculitis, have led to cautious use and may limit broader adoption, impacting revenues.
References
[1] MarketWatch. (2023). Age-related Macular Degeneration Market Size, Share & Trends. Retrieved from https://www.marketwatch.com/
[2] FDA. (2019). Beovu (brolucizumab) injection. Approved October 2019. Retrieved from https://www.fda.gov
[3] EvaluatePharma. (2022). Ophthalmology drug market analysis. Retrieved from https://www.evaluate.com
[4] IQVIA. (2022). Global ophthalmology therapeutic market statistics. Retrieved from https://www.iqvia.com
